It's Time to Move Forward


Prosigna is now included in International clinical practice guidelines

Watch now: Prosigna Breakthroughs in Early Breast Cancer at St. Gallen 2019

EMJ: GX Profiling Early ER+/HER2-Breast Cancer w/PAM50 Risk of Recurrence Assay


2018 Innovation in Oncology Highlights:


Managing patients with early-stage breast cancer begins with a highly accurate assessment of risk

Mastering the science of tumor biology

Prosigna uses the PAM50 gene signature to translate tumor biology into your patient's individualized prognostic score.

Achieving precise results

Advanced technology generates precise, reproducible prognostic information in local qualified laboratories.

Proven risk assessment you can trust

Prosigna reliably identifies your patient's 10-year risk of distant recurrence and intrinsic molecular subtype.

Proceed with confidence

Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or IIIA) early-stage breast cancer to be treated with adjuvant endocrine therapy.


© 2014-2018 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.